These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 910386)

  • 1. Uremic hyperlipoproteinemia: correlation with residual renal function and duration of maintenance hemodialysis.
    Frank W; Rao TK; Manis T; Delano BG; Avram MM; Saxena AK; Carter AC; Friedman EA
    Trans Am Soc Artif Intern Organs; 1977; 23():59-64. PubMed ID: 910386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship of plasma lipids to renal function and length of time on maintenance hemodialysis.
    Frank WM; Sreepada Rao TK; Manis T; Delano BG; Avram MM; Saxena AK; Carter AC; Friedman EA
    Am J Clin Nutr; 1978 Oct; 31(10):1886-92. PubMed ID: 707343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients.
    Chen ST; Ferng SH; Yang CS; Peng SJ; Lee HR; Chen JR
    Am J Kidney Dis; 2005 Dec; 46(6):1099-106. PubMed ID: 16310576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clofibrate treatment of hyperlipidemia in chronic renal failure.
    di Giulio S; Boulu R; Drüeke T; Nicolaĭ A; Zingraff J; Crosnier J
    Clin Nephrol; 1977 Dec; 8(6):504-9. PubMed ID: 598055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperlipidemia in patients on maintenance hemo- and peritoneal dialysis: the relative pathogenetic roles of triglyceride production and triglyceride removal.
    Chan MK; Varghese Z; Persaud JW; Baillod RA; Moorhead JF
    Clin Nephrol; 1982 Apr; 17(4):183-90. PubMed ID: 7075035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperlipidemia in uremic children: response to peritoneal dialysis and hemodialysis.
    Berger M; James GP; Davis ER; Jasper PM; Brouhard BH; Travis LB; Cunningham RJ
    Clin Nephrol; 1978 Jan; 9(1):19-24. PubMed ID: 343952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in the plasma values of glucose, free fatty acids, triglycerides and cholesterol in terminal kidney failure during hemodialysis].
    Romanov N; Shipkova P; Kiriakov Z
    Vutr Boles; 1977; 16(4):49-52. PubMed ID: 919513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipids and apolipoproteins change during the progression of chronic renal failure.
    Bergesio F; Monzani G; Ciuti R; Serruto A; Benucci A; Frizzi V; Salvadori M
    Clin Nephrol; 1992 Nov; 38(5):264-70. PubMed ID: 1451339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Variations in glycoregulatory factors during hemodialysis].
    Ducros J; Mahfoud A; Vague P; Olmer M
    J Urol Nephrol (Paris); 1978 Sep; 84(9):655-7. PubMed ID: 748586
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperglucagonemia of renal failure.
    Bilbrey GL; Faloona GR; White MG; Knochel JP
    J Clin Invest; 1974 Mar; 53(3):841-7. PubMed ID: 4812442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyslipidemia in patients with chronic renal failure and in renal transplant patients.
    Shah B; Nair S; Sirsat RA; Ashavaid TF; Nair KG
    J Postgrad Med; 1994; 40(2):57-60. PubMed ID: 8737552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dialysis hyperlipemia: response to dietary manipulations.
    Cattran DC; Steiner G; Fenton SS; Ampil M
    Clin Nephrol; 1980 Apr; 13(4):177-82. PubMed ID: 6991184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients?
    Fleischmann EH; Bower JD; Salahudeen AK
    Clin Nephrol; 2001 Sep; 56(3):221-30. PubMed ID: 11597037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
    Fiorini F; Patrone E; Castelluccio A
    Clin Ter; 1994 Sep; 145(9):213-7. PubMed ID: 7813167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of long-term hemodialysis on plasma lecithin: cholesterol acyltransferase activity and the amounts and compositions of HDL2 and HDL3 in hemodialysis-treated patients with chronic renal failure: a 9-year longitudinal study.
    Mekki K; Bouchenak M; Remaoun M; Belleville JL
    Med Sci Monit; 2004 Aug; 10(8):CR439-46. PubMed ID: 15277993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
    Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
    Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone-fuel concentrations in anephric subjects. Effect of hemodialysis (with special reference to amino acids).
    Ganda OP; Aoki TT; Soeldner JS; Morrison RS; Cahill GF
    J Clin Invest; 1976 Jun; 57(6):1403-11. PubMed ID: 932188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma concentrations of non-esterified fatty acids in chronic renal failure in the United Arab Emirates.
    Gillett MP; Obineche EN; Khan ST; Abdulle AM
    Saudi Med J; 2004 Nov; 25(11):1611-6. PubMed ID: 15573187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.